Cargando…
New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review
SIMPLE SUMMARY: In ovarian cancer, about 70% of patients experience relapse despite primary cytoreductive surgery and platinum-based chemotherapy. The occurrence of resistance to chemotherapeutic agents remains a major obstacle in this context. Various factors are involved. The use of immunotherapy...
Autor principal: | Bachmann, Cornelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669965/ https://www.ncbi.nlm.nih.gov/pubmed/38001616 http://dx.doi.org/10.3390/cancers15225356 |
Ejemplares similares
-
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction
por: Syed, Saad, et al.
Publicado: (2023) -
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022) -
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
por: Miller, Sally D, et al.
Publicado: (2022) -
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018) -
Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)